CRISPR/Cas9-Mediated Genome Editing of Herpesviruses Limits Productive and Latent Infections

PLoS Pathogens

Volumn 12, Issue 6, 2016, Pages

  van Diemen, Ferdy R ^a   Kruse, Elisabeth M ^a   Hooykaas, Marjolein J G ^a   Bruggeling, Carlijn E ^a   Schürch, Anita C ^a   van Ham, Petra M ^a   Imhof, Saskia M ^a   Nijhuis, Monique ^a   Wiertz, Emmanuel J H J ^a   Lebbink, Robert Jan ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 9;

ANIMAL CELL; ARTICLE; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; GENOME ANALYSIS; HERPES VIRUS INFECTION; HERPESVIRIDAE; HUMAN; LATENT VIRUS INFECTION; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; VIRAL PLAQUE ASSAY; CELL LINE; CRISPR CAS SYSTEM; CYTOMEGALOVIRUS; GENE EDITING; GENETICS; HERPES SIMPLEX VIRUS 1; POLYMERASE CHAIN REACTION; PROCEDURES; VIRUS GENOME; VIRUS LATENCY;

CELL LINE; CRISPR-CAS SYSTEMS; CYTOMEGALOVIRUS; GENE EDITING; GENOME, VIRAL; HERPESVIRIDAE; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 1, HUMAN; HUMANS; POLYMERASE CHAIN REACTION; VIRUS LATENCY;

EID: 84978863697     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1005701     Document Type: Article

References (92)

1. Pellett PE, Roizman B, Knipe D, Howley P, Herpesviridae. In: Fields Virology2. 6 ed: Lippincott, Williams & Wilkins; 2013. p. 1802–22.
2. Liesegang TJ, Melton LJ, 3rdDaly PJ, Ilstrup DM, Epidemiology of ocular herpes simplex. Incidence in Rochester, Minn, 1950 through 1982. Archives of ophthalmology. 1989;107(8):1155–9. Epub 1989/08/01. 2787981.
3. Hill GM, Ku ES, Dwarakanathan S, Herpes simplex keratitis. Disease-a-month: DM. 2014;60(6):239–46. Epub 2014/06/08. doi: 10.1016/j.disamonth.2014.03.00324906668.
4. Arvin AM, Gilden D, Knipe D, Howley P, Varicella-Zoster Virus. In: Fields Virology. 2. 6 ed: Lippincott Wiliams & Wilkins; 2013. p. 2015–57.
5. Mocarski ES, Shenk T, Griffiths PD, Knipe D, Howley PM, F. PR. Cytomegaloviruses. In: Fields Virology2. 6 ed: Lippincott, Williams & Wilkins; 2013. p. 1960–2014.
6. Vora SB, Englund JA, Cytomegalovirus in immunocompromised children. Current opinion in infectious diseases. 2015;28(4):323–9. Epub 2015/06/23. doi: 10.1097/QCO.000000000000017426098503.
7. Longnecker RM, Kieff E, Cohen JI, Knipe D, Howley PM, Epstein-Barr Virus. In: Fields Virology2. 6 ed: Lippincott, Williams & Wilkins; 2013. p. 1898–959.
8. Damania BA, Cesarman E, Knipe D, Howley P, Kaposi's Sarcoma-Associated Herpesvirus. In: Fields Virology. 2. 6 ed: Lippincott Wiliams & Wilkins; 2013. p. 2080–128.
9. Piret J, Boivin G, Antiviral drug resistance in herpesviruses other than cytomegalovirus. Reviews in medical virology. 2014;24(3):186–218. Epub 2014/03/08. doi: 10.1002/rmv.178724604770.
10. Andrei G, De Clercq E, Snoeck R, Raney KD, Gotte M, Cameron CE, Viral DNA Polymerase Inhibitors. In: Viral Genome Replication: Springer US; 2009. p. 481–526.
11. Price AM, Luftig MA, Dynamic Epstein-Barr virus gene expression on the path to B-cell transformation. Advances in virus research. 2014;88:279–313. Epub 2014/01/01. doi: 10.1016/B978-0-12-800098-4.00006–424373315.
12. Mali P, Esvelt KM, Church GM, Cas9 as a versatile tool for engineering biology. Nature methods. 2013;10(10):957–63. Epub 2013/10/01. doi: 10.1038/nmeth.264924076990.
13. Horvath P, Barrangou R, CRISPR/Cas, the immune system of bacteria and archaea. Science. 2010;327(5962):167–70. Epub 2010/01/09. doi: 10.1126/science.117955520056882.
14. Wiedenheft B, Sternberg SH, Doudna JA, RNA-guided genetic silencing systems in bacteria and archaea. Nature. 2012;482(7385):331–8. Epub 2012/02/18. doi: 10.1038/nature1088622337052.
15. Hsu PD, Lander ES, Zhang F, Development and applications of CRISPR-Cas9 for genome engineering. Cell. 2014;157(6):1262–78. Epub 2014/06/07. doi: 10.1016/j.cell.2014.05.01024906146.
16. Sternberg SH, Doudna JA, Expanding the Biologist's Toolkit with CRISPR-Cas9. Molecular cell. 2015;58(4):568–74. Epub 2015/05/23. doi: 10.1016/j.molcel.2015.02.03226000842.
17. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, et al. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013;339(6121):819–23. Epub 2013/01/05. doi: 10.1126/science.123114323287718; PubMed Central PMCID: PMC3795411.
18. Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, et al. RNA-guided human genome engineering via Cas9. Science. 2013;339(6121):823–6. Epub 2013/01/05. doi: 10.1126/science.123203323287722; PubMed Central PMCID: PMC3712628.
19. Mandal PK, Ferreira LM, Collins R, Meissner TB, Boutwell CL, Friesen M, et al. Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9. Cell stem cell. 2014;15(5):643–52. Epub 2014/12/18. doi: 10.1016/j.stem.2014.10.00425517468; PubMed Central PMCID: PMC4269831.
20. Wang H, Yang H, Shivalila CS, Dawlaty MM, Cheng AW, Zhang F, et al. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell. 2013;153(4):910–8. Epub 2013/05/07. doi: 10.1016/j.cell.2013.04.02523643243.
21. Yang H, Wang H, Shivalila CS, Cheng AW, Shi L, Jaenisch R, One-Step Generation of Mice Carrying Reporter and Conditional Alleles by CRISPR/Cas-Mediated Genome Engineering. Cell. 2013;154(6):1370–9. Epub 2013/09/03. doi: 10.1016/j.cell.2013.08.02223992847.
22. Li D, Qiu Z, Shao Y, Chen Y, Guan Y, Liu M, et al. Heritable gene targeting in the mouse and rat using a CRISPR-Cas system. Nature biotechnology. 2013;31(8):681–3. Epub 2013/08/10. doi: 10.1038/nbt.266123929336.
23. Bi Y, Sun L, Gao D, Ding C, Li Z, Li Y, et al. High-efficiency targeted editing of large viral genomes by RNA-guided nucleases. PLoS pathogens. 2014;10(5):e1004090. Epub 2014/05/03. doi: 10.1371/journal.ppat.100409024788700; PubMed Central PMCID: PMC4006927.
24. Kennedy EM, Kornepati AV, Goldstein M, Bogerd HP, Poling BC, Whisnant AW, et al. Inactivation of the human papillomavirus E6 or E7 gene in cervical carcinoma cells by using a bacterial CRISPR/Cas RNA-guided endonuclease. Journal of virology. 2014;88(20):11965–72. Epub 2014/08/08. doi: 10.1128/jvi.01879-1425100830; PubMed Central PMCID: PMCPmc4178730.
25. Zhen S, Hua L, Takahashi Y, Narita S, Liu YH, Li Y, In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by CRISPR/Cas9. Biochemical and biophysical research communications. 2014;450(4):1422–6. Epub 2014/07/22. doi: 10.1016/j.bbrc.2014.07.01425044113.
26. Kennedy EM, Bassit LC, Mueller H, Kornepati AV, Bogerd HP, Nie T, et al. Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease. Virology. 2014;476c:196–205. Epub 2015/01/02. doi: 10.1016/j.virol.2014.12.00125553515.
27. Russell TA, Stefanovic T, Tscharke DC, Engineering herpes simplex viruses by infection-transfection methods including recombination site targeting by CRISPR/Cas9 nucleases. Journal of virological methods. 2015;213:18–25. Epub 2014/12/06. doi: 10.1016/j.jviromet.2014.11.00925479355.
28. Suenaga T, Kohyama M, Hirayasu K, Arase H, Engineering large viral DNA genomes using the CRISPR-Cas9 system. Microbiology and immunology. 2014;58(9):513–22. Epub 2014/07/22. doi: 10.1111/1348-0421.1218025040500.
29. Wang J, Quake SR, RNA-guided endonuclease provides a therapeutic strategy to cure latent herpesviridae infection. Proceedings of the National Academy of Sciences of the United States of America. 2014;111(36):13157–62. Epub 2014/08/27. doi: 10.1073/pnas.141078511125157128.
30. Wollebo HS, Bellizzi A, Kaminski R, Hu W, White MK, Khalili K, CRISPR/Cas9 System as an Agent for Eliminating Polyomavirus JC Infection. PloS one. 2015;10(9):e0136046. Epub 2015/09/12. doi: 10.1371/journal.pone.013604626360417; PubMed Central PMCID: PMC4567079.
31. Price AA, Sampson TR, Ratner HK, Grakoui A, Weiss DS, Cas9-mediated targeting of viral RNA in eukaryotic cells. Proceedings of the National Academy of Sciences of the United States of America. 2015;112(19):6164–9. Epub 2015/04/29. doi: 10.1073/pnas.142234011225918406; PubMed Central PMCID: PMC4434742.
32. Ebina H, Misawa N, Kanemura Y, Koyanagi Y, Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus. Scientific reports. 2013;3:2510. Epub 2013/08/27. doi: 10.1038/srep0251023974631; PubMed Central PMCID: PMCPmc3752613.
33. Hu W, Kaminski R, Yang F, Zhang Y, Cosentino L, Li F, et al. RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. Proceedings of the National Academy of Sciences of the United States of America. 2014;111(31):11461–6. Epub 2014/07/23. doi: 10.1073/pnas.140518611125049410; PubMed Central PMCID: PMCPmc4128125.
34. Liao HK, Gu Y, Diaz A, Marlett J, Takahashi Y, Li M, et al. Use of the CRISPR/Cas9 system as an intracellular defense against HIV-1 infection in human cells. Nature communications. 2015;6:6413. Epub 2015/03/11. doi: 10.1038/ncomms741325752527.
35. Zhang Y, Yin C, Zhang T, Li F, Yang W, Kaminski R, et al. CRISPR/gRNA-directed synergistic activation mediator (SAM) induces specific, persistent and robust reactivation of the HIV-1 latent reservoirs. Scientific reports. 2015;5:16277. Epub 2015/11/06. doi: 10.1038/srep1627726538064; PubMed Central PMCID: PMC4633726.
36. Kaminski R, Chen Y, Fischer T, Tedaldi E, Napoli A, Zhang Y, et al. Elimination of HIV-1 Genomes from Human T-lymphoid Cells by CRISPR/Cas9 Gene Editing. Scientific reports. 2016;6:22555. doi: 10.1038/srep2255526939770; PubMed Central PMCID: PMCPMC4778041.
37. Reisman D, Yates J, Sugden B, A putative origin of replication of plasmids derived from Epstein-Barr virus is composed of two cis-acting components. Molecular and cellular biology. 1985;5(8):1822–32. Epub 1985/08/01. 3018528; PubMed Central PMCID: PMCPmc366897.
38. Rawlins DR, Milman G, Hayward SD, Hayward GS, Sequence-specific DNA binding of the Epstein-Barr virus nuclear antigen (EBNA-1) to clustered sites in the plasmid maintenance region. Cell. 1985;42(3):859–68. Epub 1985/10/01. 2996781.
39. Molesworth SJ, Lake CM, Borza CM, Turk SM, Hutt-Fletcher LM, Epstein-Barr virus gH is essential for penetration of B cells but also plays a role in attachment of virus to epithelial cells. Journal of virology. 2000;74(14):6324–32. Epub 2000/06/23. 10864642; PubMed Central PMCID: PMCPmc112138.
40. Yu D, Silva MC, Shenk T, Functional map of human cytomegalovirus AD169 defined by global mutational analysis. Proceedings of the National Academy of Sciences of the United States of America. 2003;100(21):12396–401. Epub 2003/10/02. doi: 10.1073/pnas.163516010014519856; PubMed Central PMCID: PMCPmc218769.
41. Dunn W, Chou C, Li H, Hai R, Patterson D, Stolc V, et al. Functional profiling of a human cytomegalovirus genome. Proceedings of the National Academy of Sciences of the United States of America. 2003;100(24):14223–8. Epub 2003/11/19. doi: 10.1073/pnas.233403210014623981; PubMed Central PMCID: PMCPmc283573.
42. Sampaio KL, Cavignac Y, Stierhof YD, Sinzger C, Human cytomegalovirus labeled with green fluorescent protein for live analysis of intracellular particle movements. Journal of virology. 2005;79(5):2754–67. Epub 2005/02/15. doi: 10.1128/jvi.79.5.2754–2767.200515708994; PubMed Central PMCID: PMCPmc548422.
43. Spector DJ, Yetming K, UL84-independent replication of human cytomegalovirus strain TB40/E. Virology. 2010;407(2):171–7. Epub 2010/09/22. doi: 10.1016/j.virol.2010.08.02920855098.
44. McGeoch DJ, Rixon FJ, Davison AJ, Topics in herpesvirus genomics and evolution. Virus research. 2006;117(1):90–104. Epub 2006/02/24. doi: 10.1016/j.virusres.2006.01.00216490275.
45. Crute JJ, Mocarski ES, Lehman IR, A DNA helicase induced by herpes simplex virus type 1. Nucleic acids research. 1988;16(14A):6585–96. Epub 1988/07/25. 2840645; PubMed Central PMCID: PMC338315.
46. Crute JJ, Tsurumi T, Zhu LA, Weller SK, Olivo PD, Challberg MD, et al. Herpes simplex virus 1 helicase-primase: a complex of three herpes-encoded gene products. Proceedings of the National Academy of Sciences of the United States of America. 1989;86(7):2186–9. Epub 1989/04/01. 2538835; PubMed Central PMCID: PMC286876.
47. Russell J, Preston CM, An in vitro latency system for herpes simplex virus type 2. The Journal of general virology. 1986;67 (Pt 2):397–403. Epub 1986/02/01. doi: 10.1099/0022-1317-67-2-3973003243.
48. Russell J, Stow ND, Stow EC, Preston CM, Herpes simplex virus genes involved in latency in vitro. The Journal of general virology. 1987;68 (Pt 12):3009–18. Epub 1987/12/01. doi: 10.1099/0022-1317-68-12-30092826646.
49. Feng WH, Hong G, Delecluse HJ, Kenney SC, Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas. Journal of virology. 2004;78(4):1893–902. Epub 2004/01/30. 14747554; PubMed Central PMCID: PMCPmc369434.
50. Elbadawy HM, Gailledrat M, Desseaux C, Salvalaio G, Di Iorio E, Ferrari B, et al. Gene transfer of integration defective anti-HSV-1 meganuclease to human corneas ex vivo. Gene therapy. 2014;21(3):272–81. Epub 2014/01/17. doi: 10.1038/gt.2013.8224430237.
51. Aubert M, Boyle NM, Stone D, Stensland L, Huang ML, Magaret AS, et al. In vitro Inactivation of Latent HSV by Targeted Mutagenesis Using an HSV-specific Homing Endonuclease. Molecular therapy Nucleic acids. 2014;3:e146. Epub 2014/02/06. doi: 10.1038/mtna.2013.7524496438; PubMed Central PMCID: PMCPmc3951911.
52. Reisman D, Sugden B, trans activation of an Epstein-Barr viral transcriptional enhancer by the Epstein-Barr viral nuclear antigen 1. Molecular and cellular biology. 1986;6(11):3838–46. Epub 1986/11/01. 3025615; PubMed Central PMCID: PMCPmc367146.
53. Sugden B, Marsh K, Yates J, A vector that replicates as a plasmid and can be efficiently selected in B-lymphoblasts transformed by Epstein-Barr virus. Molecular and cellular biology. 1985;5(2):410–3. Epub 1985/02/01. 2983194; PubMed Central PMCID: PMCPmc366725.
54. Yates JL, Warren N, Sugden B, Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature. 1985;313(6005):812–5. Epub 1985/02/06. 2983224.
55. Yin Q, Flemington EK, siRNAs against the Epstein Barr virus latency replication factor, EBNA1, inhibit its function and growth of EBV-dependent tumor cells. Virology. 2006;346(2):385–93. Epub 2005/12/14. doi: 10.1016/j.virol.2005.11.02116343579.
56. Lee EK, Kim SY, Noh KW, Joo EH, Zhao B, Kieff E, et al. Small molecule inhibition of Epstein-Barr virus nuclear antigen-1 DNA binding activity interferes with replication and persistence of the viral genome. Antiviral research. 2014;104:73–83. Epub 2014/02/04. doi: 10.1016/j.antiviral.2014.01.01824486954; PubMed Central PMCID: PMCPmc3964181.
57. Kang MS, Lee EK, Soni V, Lewis TA, Koehler AN, Srinivasan V, et al. Roscovitine inhibits EBNA1 serine 393 phosphorylation, nuclear localization, transcription, and episome maintenance. Journal of virology. 2011;85(6):2859–68. Epub 2011/01/07. doi: 10.1128/jvi.01628-1021209116; PubMed Central PMCID: PMCPmc3067954.
58. Nasimuzzaman M, Kuroda M, Dohno S, Yamamoto T, Iwatsuki K, Matsuzaki S, et al. Eradication of Epstein-Barr virus episome and associated inhibition of infected tumor cell growth by adenovirus vector-mediated transduction of dominant-negative EBNA1. Molecular therapy: the journal of the American Society of Gene Therapy. 2005;11(4):578–90. Epub 2005/03/18. doi: 10.1016/j.ymthe.2004.12.01715771960.
59. Kim do N, Seo MK, Choi H, Kim SY, Shin HJ, Yoon AR, et al. Characterization of naturally Epstein-Barr virus-infected gastric carcinoma cell line YCCEL1. The Journal of general virology. 2013;94(Pt 3):497–506. Epub 2012/11/24. doi: 10.1099/vir.0.045237–023175241.
60. Zheng Q, Cai X, Tan MH, Schaffert S, Arnold CP, Gong X, et al. Precise gene deletion and replacement using the CRISPR/Cas9 system in human cells. BioTechniques. 2014;57(3):115–24. Epub 2014/09/12. doi: 10.2144/00011419625209046.
61. Yuen KS, Chan CP, Wong NH, Ho CH, Ho TH, Lei T, et al. CRISPR/Cas9-mediated genome editing of Epstein-Barr virus in human cells. The Journal of general virology. 2015;96(Pt 3):626–36. Epub 2014/12/17. doi: 10.1099/jgv.0.00001225502645.
62. Riballo E, Kuhne M, Rief N, Doherty A, Smith GC, Recio MJ, et al. A pathway of double-strand break rejoining dependent upon ATM, Artemis, and proteins locating to gamma-H2AX foci. Molecular cell. 2004;16(5):715–24. Epub 2004/12/03. doi: 10.1016/j.molcel.2004.10.02915574327.
63. Rajcani J, Durmanova V, Mechanisms of replication of alpha- and betaherpesviruses and their pathogenesis. Bratislavske lekarske listy. 2001;102(11):505–14. Epub 2002/03/21. 11901707.
64. Doench JG, Hartenian E, Graham DB, Tothova Z, Hegde M, Smith I, et al. Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation. Nature biotechnology. 2014;32(12):1262–7. Epub 2014/09/04. doi: 10.1038/nbt.302625184501; PubMed Central PMCID: PMC4262738.
65. Kuscu C, Arslan S, Singh R, Thorpe J, Adli M, Genome-wide analysis reveals characteristics of off-target sites bound by the Cas9 endonuclease. Nature biotechnology. 2014;32(7):677–83. Epub 2014/05/20. doi: 10.1038/nbt.291624837660.
66. Wu X, Scott DA, Kriz AJ, Chiu AC, Hsu PD, Dadon DB, et al. Genome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells. Nature biotechnology. 2014;32(7):670–6. Epub 2014/04/23. doi: 10.1038/nbt.288924752079; PubMed Central PMCID: PMC4145672.
67. Pybus OG, Rambaut A, Evolutionary analysis of the dynamics of viral infectious disease. Nature reviews Genetics. 2009;10(8):540–50. Epub 2009/07/01. doi: 10.1038/nrg258319564871.
68. Sakaoka H, Kurita K, Iida Y, Takada S, Umene K, Kim YT, et al. Quantitative analysis of genomic polymorphism of herpes simplex virus type 1 strains from six countries: studies of molecular evolution and molecular epidemiology of the virus. The Journal of general virology. 1994;75 (Pt 3):513–27. Epub 1994/03/01. 8126449.
69. Fu Y, Foden JA, Khayter C, Maeder ML, Reyon D, Joung JK, et al. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nature biotechnology. 2013;31(9):822–6. Epub 2013/06/25. doi: 10.1038/nbt.262323792628; PubMed Central PMCID: PMCPmc3773023.
70. Ran FA, Hsu PD, Lin CY, Gootenberg JS, Konermann S, Trevino AE, et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell. 2013;154(6):1380–9. Epub 2013/09/03. doi: 10.1016/j.cell.2013.08.02123992846; PubMed Central PMCID: PMC3856256.
71. Fu Y, Sander JD, Reyon D, Cascio VM, Joung JK, Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nature biotechnology. 2014;32(3):279–84. Epub 2014/01/28. doi: 10.1038/nbt.280824463574; PubMed Central PMCID: PMCPmc3988262.
72. Kleinstiver BP, Pattanayak V, Prew MS, Tsai SQ, Nguyen NT, Zheng Z, et al. High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature. 2016;529(7587):490–5. Epub 2016/01/07. doi: 10.1038/nature1652626735016.
73. Kleinstiver BP, Prew MS, Tsai SQ, Topkar VV, Nguyen NT, Zheng Z, et al. Engineered CRISPR-Cas9 nucleases with altered PAM specificities. Nature. 2015;523(7561):481–5. Epub 2015/06/23. doi: 10.1038/nature1459226098369; PubMed Central PMCID: PMC4540238.
74. Slaymaker IM, Gao L, Zetsche B, Scott DA, Yan WX, Zhang F, Rationally engineered Cas9 nucleases with improved specificity. Science. 2016;351(6268):84–8. Epub 2015/12/03. doi: 10.1126/science.aad522726628643; PubMed Central PMCID: PMC4714946.
75. Nicoll MP, Proenca JT, Efstathiou S, The molecular basis of herpes simplex virus latency. FEMS microbiology reviews. 2012;36(3):684–705. Epub 2011/12/14. doi: 10.1111/j.1574-6976.2011.00320.x22150699; PubMed Central PMCID: PMC3492847.
76. Coleman HM, Connor V, Cheng ZS, Grey F, Preston CM, Efstathiou S, Histone modifications associated with herpes simplex virus type 1 genomes during quiescence and following ICP0-mediated de-repression. The Journal of general virology. 2008;89(Pt 1):68–77. Epub 2007/12/20. doi: 10.1099/vir.0.83272–018089730; PubMed Central PMCID: PMC2884978.
77. Ferenczy MW, Ranayhossaini DJ, Deluca NA, Activities of ICP0 involved in the reversal of silencing of quiescent herpes simplex virus 1. Journal of virology. 2011;85(10):4993–5002. Epub 2011/03/18. doi: 10.1128/JVI.02265-1021411540; PubMed Central PMCID: PMC3126212.
78. Wang D, Gao G, State-of-the-art human gene therapy: part II. Gene therapy strategies and clinical applications. Discovery medicine. 2014;18(98):151–61. Epub 2014/09/18. 25227756.
79. Flotte TR, Birth of a new therapeutic platform: 47 years of adeno-associated virus biology from virus discovery to licensed gene therapy. Molecular therapy: the journal of the American Society of Gene Therapy. 2013;21(11):1976–81. Epub 2013/11/10. doi: 10.1038/mt.2013.22624201212; PubMed Central PMCID: PMCPmc3831048.
80. Wang D, Gao G, State-of-the-art human gene therapy: part I. Gene delivery technologies. Discovery medicine. 2014;18(97):67–77. Epub 2014/08/06. 25091489.
81. Bartlett JS, Samulski RJ, McCown TJ, Selective and rapid uptake of adeno-associated virus type 2 in brain. Human gene therapy. 1998;9(8):1181–6. Epub 1998/06/13. doi: 10.1089/hum.1998.9.8–11819625257.
82. D'Astolfo DS, Pagliero RJ, Pras A, Karthaus WR, Clevers H, Prasad V, et al. Efficient intracellular delivery of native proteins. Cell. 2015;161(3):674–90. Epub 2015/04/25. doi: 10.1016/j.cell.2015.03.02825910214.
83. Zuris JA, Thompson DB, Shu Y, Guilinger JP, Bessen JL, Hu JH, et al. Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. Nature biotechnology. 2015;33(1):73–80. Epub 2014/10/31. doi: 10.1038/nbt.308125357182; PubMed Central PMCID: PMC4289409.
84. Terhune S, Torigoi E, Moorman N, Silva M, Qian Z, Shenk T, et al. Human cytomegalovirus UL38 protein blocks apoptosis. Journal of virology. 2007;81(7):3109–23. Epub 2007/01/05. doi: 10.1128/jvi.02124-0617202209; PubMed Central PMCID: PMCPmc1866066.
85. La Boissiere S, Izeta A, Malcomber S, O'Hare P, Compartmentalization of VP16 in cells infected with recombinant herpes simplex virus expressing VP16-green fluorescent protein fusion proteins. Journal of virology. 2004;78(15):8002–14. Epub 2004/07/16. doi: 10.1128/JVI.78.15.8002–8014.200415254172; PubMed Central PMCID: PMC446094.
86. Ventura A, Meissner A, Dillon CP, McManus M, Sharp PA, Van Parijs L, et al. Cre-lox-regulated conditional RNA interference from transgenes. Proceedings of the National Academy of Sciences of the United States of America. 2004;101(28):10380–5. Epub 2004/07/09. doi: 10.1073/pnas.040395410115240889; PubMed Central PMCID: PMCPmc478580.
87. Osborn MJ, Panoskaltsis-Mortari A, McElmurry RT, Bell SK, Vignali DA, Ryan MD, et al. A picornaviral 2A-like sequence-based tricistronic vector allowing for high-level therapeutic gene expression coupled to a dual-reporter system. Molecular therapy: the journal of the American Society of Gene Therapy. 2005;12(3):569–74. Epub 2005/06/21. doi: 10.1016/j.ymthe.2005.04.01315964244.
88. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E, A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337(6096):816–21. Epub 2012/06/30. doi: 10.1126/science.122582922745249.
89. van de Weijer ML, Bassik MC, Luteijn RD, Voorburg CM, Lohuis MA, Kremmer E, et al. A high-coverage shRNA screen identifies TMEM129 as an E3 ligase involved in ER-associated protein degradation. Nature communications. 2014;5:3832. Epub 2014/05/09. doi: 10.1038/ncomms483224807418; PubMed Central PMCID: PMCPmc4024746.
90. Langmead B, Salzberg SL, Fast gapped-read alignment with Bowtie 2. Nature methods. 2012;9(4):357–9. Epub 2012/03/06. doi: 10.1038/nmeth.192322388286; PubMed Central PMCID: PMC3322381.
91. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics. 2009;25(16):2078–9. Epub 2009/06/10. doi: 10.1093/bioinformatics/btp35219505943; PubMed Central PMCID: PMC2723002.
92. Milne I, Stephen G, Bayer M, Cock PJA, Pritchard L, Cardle L, et al. Using Tablet for visual exploration of second-generation sequencing data. Brief Bioinform. 2013;14(2):193–202. doi: 10.1093/bib/bbs012ISI:000316694700007.